Insmed thanks you for attending ATS 2025. We hope you were able to stop by our booth focused on bronchiectasis and its exacerbations. For more information about bronchiectasis, you can visit RethinkBronchiectasis.com. NP-BE-US-00777.

We hope you are enjoying ATS 2025. Be sure to stop by Booth #1839, where you can find information about bronchiectasis exacerbations and their key drivers. Insmed looks forward to seeing you at our booth. NP-BE-US-00777

Please join us at ATS 2025 in San Francisco for an educational symposium. On Monday, May 19, 2025, from 6:30-8:00 PM PDT, Drs Mario Castro and Alberto Papi will explore the similarities and differences across asthma and COPD, present biologic data in these two diseases, and discuss the value of early intervention and the potential for disease modification in the lower airway. The learning objectives of the symposium are to identify the roles that type 2 inflammation plays in the pathophysiology and disease progression of asthma and COPD. Participants will gain an understanding of airway remodeling in asthma and how intervention may impact these processes. Additionally, the symposium will provide insights into relevant clinical data related to COPD. Don’t miss your opportunity to interact with the faculty during the live audience Q&A following the presentations.

Bruce Trapnell, MD, and Cormac McCarthy, MD, PhD, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, its signs and symptoms, burden of illness, and diagnosis and management of the disease.

Please join us at ATS 2025 in San Francisco for an educational symposium. On Sunday, May 18th, from 6:30-7:30 PM PDT, Drs Nicola Hanania, Lauren Cohn, and Klaus Rabe will discuss the burden of COPD, the role of IL-33 in disease pathophysiology, and key insights from clinical trials. The learning objectives of the symposium are to communicate the burden of COPD, focusing on its impact on patients’ quality of life and persistent unmet needs. The session will also explore the role of IL-33 in the pathophysiology of COPD, emphasizing its contribution to inflammation, airway remodeling, and disease progression. Additionally, the symposium will provide an overview of the clinical trial data related to targeting the IL-33 pathway in COPD. Don’t miss your opportunity to interact with the faculty during the live audience Q&A following the presentation.

Join us on Monday, May 19 at 6:30pm in the Golden Gate Ballroom A/B at the San Francisco Marriott Marquis as two expert pulmonologists share their different perspectives of diagnosing and managing patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases in both academic and private practice settings. They will share insights into delays in diagnosis, the importance of high resolution computed tomography (HRCT) imaging, and challenges and unmet educational needs that physicians and patients may face. During this program, attendees will also hear directly from a patient living with IPF and learn more about her journey.

This presentation explores the cascading impact of the ST2/IL-33 pathway on regulating neutrophilic (type 1 and type 3) and eosinophilic (type 2) inflammation in COPD.1,2 Learn how insights into COPD pathophysiology are helping to identify new ways to impact underlying disease mechanisms and inflammatory pathways involved in COPD.1

Join Clinical Care Options for 2 dynamic evenings of expert-led education focused on advancing care in obstructive sleep apnea (OSA) and non–cystic fibrosis bronchiectasis (NCFBE). Sunday, May 18: Breaking the Cycle: Prioritizing Weight Loss to Improve OSA Management will explore the critical connection between obesity and OSA and how weight management strategies can improve patient outcomes. This program will also be available virtually. Monday, May 19: The Road to Victory Over the Vortex: Innovations in Non–Cystic Fibrosis Bronchiectasis highlights novel approaches and breakthroughs in the diagnosis and treatment of NCFBE. Both events will be held at the W San Francisco. Don’t miss this opportunity to enhance your clinical practice with the latest insights and practical strategies from leading experts in pulmonary medicine. Reserve your spot today for one—or both—of these impactful educational experiences.

Refractory chronic cough, or RCC, is a distinct disease identified in a subset of people who experience chronic cough despite adequate treatment for known cough-related etiologies.1-3 RCC is associated with neuronal hypersensitivity and hyper-responsiveness.1,4 Join us in Innovation Theater 1 on Tuesday, May 20th from 1:30-2:15 PM for our multidisciplinary expert panel, ‘Cough and Effect: Diagnosing Refractory Chronic Cough with Speed and Precision.’ Specialists will review and discuss hypothetical cases and offer insights on the optimal approach to diagnosing RCC. Don’t forget to stop by the GSK Medical booth to explore the path to RCC diagnosis with our arcade-style racing game, RCC Raceway! References: 1. Chung et al. Nat Rev Dis Primers. 2022.8(1):45; 2. Irwin RS, et al. Chest. 2018;153:196– 209; 3. Morice AH, et al. Eur Respir J. 2020;55:1901136; 4. Satia I, et al. Clin Med. 2016;16(6):s92–s97.

Join us at the American Thoracic Society (ATS) conference, booth 659, to discover how MannKind is pioneering advancements to ease the burden of serious diseases, especially in chronic lung disease. Be among the first to learn about what’s coming down the pipeline for nontuberculous mycobacterial (NTM) lung disease.

Please join us at ATS 2025 in San Francisco for two educational symposia. On Sunday, May 18, 2025, from 6:30-7:30 PM PDT, Drs Nicola Hanania, Lauren Cohn, and Klaus Rabe will discuss the burden of COPD, the role of IL-33 in disease pathophysiology, and key insights from clinical trials. On Monday, May 19, 2025, from 6:30-8:00 PM PDT, Drs Mario Castro and Alberto Papi will explore the similarities and differences across asthma and COPD, present biologic data in these two diseases, and discuss the value of early intervention and the potential for disease modification in the lower airway. Don’t miss your opportunity to interact with the faculty during the live audience Q&A following the presentations.

Join Patrick Flume, MD, at 11:30 AM on Monday, May 19, in Innovation Theater 3 as he discusses the burden, causes, and management of bronchiectasis exacerbations. The presentation will focus on the key drivers of bronchiectasis, including the critical role of inflammation. NP-BE-US-00777.